An interventional study of Intranasal oxytocin and Intranasal placebo in Healthy, sponsored by University of Electronic Science and Technology of China. Completed at 1 site in China. Open to male participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-14.
Sponsored by University of Electronic Science and Technology of China · Not applicable, Interventional, and Basic science
The main aim of the study is to investigate whether intranasal oxytocin modulates advantageous- and disadvantageous-inequity and whether oxytocin has similar effects on them or not.
The main aim of the study is to investigate whether intranasal oxytocin modulates advantageous- and disadvantageous-inequity and its underlying neural mechanisms and whether oxytocin has similar effects on them or not. A double-blinded, placebo-controled, between-subject design is employed in this study. In a randomized order, a total of 80 healthy males are instructed to self-administrated intranasal spray of oxytocin or placebo. A modified inequity decision-making task starts 45 minutes after treatment with behavioral (fairness rating, preference rating and the choice rate of unequal option) and fMRI data being collected during this task. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), Sensitivity to Punishment and Sensitivity to Reward Questionnaire (SPSRQ), Behavioral Inhibition System and Behavioral Activation System Scale (BIS/BAS). Subjects are asked to complete Positive and Negative Affect Schedule (PANAS) when they just arrive, before and after the task.
University of Electronic Science and Technology of China is the lead sponsor of 109 studies on the registry; 35 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
a single dose of 24 international units (IU) of OT will be administered with 3 puffs of treatment to each nostril.
Drug: Intranasal oxytocin
a single dose of 24 international units (IU) of placebo will be administered with 3 puffs of treatment to each nostril.
Drug: Intranasal placebo
Subject assigned to receive intranasal administration of oxytocin (24 IU).
Subjects assigned to receive intranasal administration of placebo (24 IU).
Behavioral index: fairness rating scores
Participants are instructed to rate their perceived levels of fairness to the allocation using a 9-point Likert scale within 4 seconds (1 = very unfair, 9 = very fair).
Time frame: 45-75 minutes after treatment administration
Behavioral index: preference rating scores
Participants are instructed to rate their perceived levels of preference to the allocation using a 9-point Likert scale within 4 seconds (1 = not at all, 9 = very preferable).
Time frame: 45-75 minutes after treatment administration
Neural indices: fMRI-based measures of the outcome presentation stage
Functional magnetic resonance imaging (fMRI) is employed to assess participants' blood-oxygen-level dependent signals when they are confronted with monetary allocations (advantageous-inequity, disadvantageous-inequity, and fair).
Time frame: 45-75 minutes after treatment administration
Behavioral index: choice rate of unequal option
Participants are instructed to make a hypothetical choice between the actual allocation in the current trial and the other fair option if they were given another chance to re-choose.
Time frame: 45-75 minutes after treatment administration
Neural indices: fMRI-based measures of outcome and re-decision stages
Functional magnetic resonance imaging (fMRI) is employed to assess participants' blood-oxygen-level dependent signals when they are instructed to make a hypothetical choice between the actual allocation in the current trial and the other fair option if they were given another chance to re-choose.
Time frame: 45-75 minutes after treatment administration
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Electronic Science and Technology of China